Emergency brain resuscitation

Comprehensive Therapy

Volumn 23, Issue 6, 1997, Pages 391-399

  Alberts, Mark J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APTIGANEL; FIBRINOLYTIC AGENT; HEPARIN; LUBELUZOLE; NEUROPROTECTIVE AGENT; PLACEBO; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; EMERGENCY TREATMENT; HEALTH EDUCATION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL EDUCATION; PATIENT CARE; RESUSCITATION; REVIEW; TEAMWORK;

CEREBROVASCULAR DISORDERS; EMERGENCIES; HEALTH EDUCATION; HEALTH PERSONNEL; HUMANS; PATIENT CARE TEAM; PLASMINOGEN ACTIVATORS; RESUSCITATION; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030787988     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. A Working Group on Emergency Brain Resuscitation. Emergency brain resuscitation. Ann Intern Med. 1995;122:622-627.
2. Alberts M. The Stroke Belt Consortium. J Stroke Cerebrovascular Dis. 1996;6:54-58.
3. Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke. 1995;26:2219-2221. Editorial.
4. Camarata PJ, Heros RC, Latchaw RE. "Brain attack": the rationale for treating stroke as a medical emergency. Neurosurgery. 1994;34:144-157; discussion 157-158.
5. Futrell N, Millikan CH. Stroke is an emergency. Dis Mon. 1996;42:199-264.
6. Gomez CR, Malkoff MD, Sauer CM, et al. Code stroke: an attempt to shorten inhospital therapeutic delays. Stroke. 1994;25:1920-1923.
7. NSA/Gallup. National Stroke Awareness Survey. The Gallup Organization; 1991.
8. Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol. 1994;36:557-565.
9. Fisher M, Takano K. The penumbra, therapeutic time window and acute ischaemic stroke. Baillieres Clin NeuroL 1995;4:279-295.
10. Heiss WD, Graf R. The ischemic penumbra. Curr Opin Neurol. 1994;7:11-19.
11. Furlan M, Marchal G, Viader F, et al. Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra. Ann Neurol. 1996;40:216-226.
12. Ginsberg M, Pulsinelli W. The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke. Ann Neurol. 1994;36:553-554.
13. Marchal G, Beaudouin V, Rioux P, et al. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: a correlative PET-CT study with voxel-based data analysis. Strode. 1996;27:599-606.
14. Foulkes MA, Wolf PA, Price TR, et al. The Stroke Data Bank. Stroke. 1988;19:547-552.
15. Alberts MJ, Bertels C, Dawson DV. An analysis of time of presentation after stroke. JAMA. 1990;263:65-68.
16. Grotta J. The Importance of Time. Presented at A National Symposium on Rapid Identification of Acute Stroke. Dec 12-13, 1996. Arlington, VA: The National Institute of Neurological Disorders and Stroke.
17. Alberts MJ, Perry A, Dawson DV, et al. Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. Stroke. 1992;23:352-356.
18. Barsan WG, Brott TG, Broderick JP, et al. Urgent therapy for acute stroke: effects of a stroke trial on untreated patients. Stroke. 1994;25:2132-2137.
19. Barsan WG, Brott TG, Broderick JP, et al. Time of hospital presentation in patients with acute stroke. Arch Intern Med. 1993;153:2558-2561.
20. McGovern PG, Burke GL, Sprafka JM, et al. Trends in mortality, morbidity, and risk factor levels for stroke from 1960 through 1990: The Minnesota Heart Survey. JAMA. 1992;268:753-759.
21. Alberts MJ, Brass LM, Perry A, et al. Evaluation times for patients with in-hospital stroke. Stroke. 1993;24:1817-1822.
22. Alberts M. Undergraduate and postgraduate medical education for cerebrovascular disease. Stroke. 1995;26:1849-1851.
23. Bratina P, Greenberg L, Pasteur W, et al. Current emergency department management of stroke in Houston, Texas. Stroke. 1995;26:409-414.
24. A National Symposium on Rapid Identification of Acute Stroke. Dec 12-13, 1996. Arlington, VA: The National Institute of Neuological Disorders and Stroke.
25. Webb D, Fayad P, Wilbur C, et al. Effects of a specialized team on stroke care. Stroke. 1993;24:176.
26. Mitchell J, Ballard D, Whisnant J, et al. What role do neurologists play in determining the costs and outcomes of stroke patients. Stroke. 1996;27:1937-1943.
27. Kothari R, Barsan W, Brott T, et al. Frequency and accuracy of prehospital diagnosis of acute stroke. Stroke. 1995;26:937-941.
28. Adams H, Brott T, Crowell R, et al. Guidelines for the management of patients with acute ischemic stroke. Stroke. 1994;25:1901-1914.
29. Horner J, Massey E, Ruki J, et al. Aspiration following stroke: clinical correlation and outcome. Neurol. 1988;38:1359-1362.
30. Pulsinelli W, Waldman S, Rawlinson D, et al. Moderate hyperglycemia augments ischemic brain damage: a neuropathologic study in the rat. Neurol. 1982;32:1239-1246.
31. Wass C, Lanier W. Glucose modulation of ischemic brain injury: review and clinical recommendations. Mayo Clin Proc. 1996;71:801-812.
32. Activase, Alteplase recombinant for acute ischemic stroke. Presented at the Peripheral and Central Nervous System Drug Advisory Committee Meeting. June 6, 1996, Bethesda, MD.
33. The National Institute of Neurologic Disorders and Stroke rt-PA Acute Stroke Study Group. Tissue Plasminogen Activator in Acute Ischemic Stroke. N Engl J Med. 1995;33;1581-1587.
34. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA. 1996;276:961-966.
35. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of Streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514.
36. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with Streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145-150.
37. Anonymous. Streptase. Physicians' Desk Reference. Montvale, NJ: Medical Economics Data; 1993:656-658.
38. Barr JD, Mathis JM, Wildenhain SL, et al. Acute stroke intervention with intraarterial urokinase infusion. J Vasc Interv Radiol. 1994;5:705-713.
39. Barnwell SL, Nesbit GM, Clark WM. Local thrombolytic therapy for cerebrovascular disease: current Oregon Health Sciences University experience (July 1991 through April 1995). J Vasc Interv Radiol. 1995;6(suppl):78S-82S.
40. Castillo J, Davalos A, Naveiro J, et al. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke. 1996;27:1060-1065.
41. Takagi K, Ginsberg MD, Globus MY, et al. Changes in amino acid neurotransmitters and cerebral blood flow in the ischemic penumbra region following middle cerebral artery occlusion in the rat: correlation with histopathology. J Cereb Blood Flow Metab. 1993;13:575-585.
42. Siesjo BK, Zhao Q, Pahlmark K, et al. Glutamate, calcium, and free radicals as mediators of ischemic brain damage. Ann Thorac Surg. 1995;59:1316-1320.
43. Chan PH. Oxygen radicals in focal cerebral ischemia. Brain Pathol. 1994;4:59-65.
44. Cowley DJ, Lukovic L, Petty MA. MDL 74,180 reduces cerebral infarction and free radical concentrations in rats subjected to ischaemia and reperfusion. Eur J Pharmacol. 1996;298:227-233.
45. Chan PH. Role of oxidants in ischemic brain damage. Stroke. 1996;27:1124-1129.
46. Diener H, Hacke W, Hennerici M, et al. Lubeluzole in acute ischemic stroke: a double-blind, placebo-controlled phase II trial. Stroke. 1996;27:76-81.
47. Muir K, Lees K. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
48. Zivin J, Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol. 1991;48:1235-1238.